Characteristics of patients, MPN, and subsequent lymphoma
| Patient no. . | Sex . | MF Dx date . | Prior MPN . | Molecular (allele %) . | LDH at MF Dx . | Marrow fibrosis grade . | Cytogenetics at time of MF Dx . | Prior MPN therapies before JAK inhibitor . | JAK inhibitor received . | JAK inhibitor prior to lymphoma? . | Lymphoma Dx date . | Age at lymphoma Dx . | Lymphoma stage . | Lymphoma subtype . | Lymphoma treatment . | OS from lymphoma Dx . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 8/14/2000 | No | Not done | 569 | MF-2 | Diploid | HU | N/A | N | 3/22/2010 | 62 | I | Follicular lymphoma, grade 3A | Observation | 11 mo |
| 2 | M | 3/26/2012 | No | JAK2 (46.4%) | 1107 | MF-2 | Diploid | None | N/A | N | 4/12/2012 | 62 | IV | Enteropathy associated TCL | Observation | NR |
| 3 | F | 7/23/2013 | PV | JAK2 (42.1%) | 949 | MF-2 | 46,XX,t(9;15) (p24;q15) | HU+ phlebotomy | N/A | N | 9/3/2013 | 63 | IV | TCL, anaplastic, ALK− | CHOP | 1.6 mo |
| 4 | M | 3/9/2010 | PV | JAK2 (86%) | 916 | MF-2 | 46,XY,del(20) (q11.2q13.3) | None | Len + Rux | Y | 7/13/2015 | 54 | IV | DLBCL | R-EPOCH | Lost to follow-up |
| 5 | F | 11/30/2010 | No | Triple-negative MF | 763 | MF-2 | Diploid | None | Rux | Y | 1/15/2017 | 69 | Unknown | NHL (scalp) | Lost to follow-up | Lost to follow-up |
| 6 | M | 2/21/2006 | No | Not done | 1635 | MF-2 | Diploid | None | CEP-701 | Y | 8/7/2014 | 49 | IV | DLBCL | R-CHOP/HD MTX | 5.5 mo |
| 7 | M | 6/27/2008 | PV | JAK2 (82%) | 1134 | MF-3 | 46,XY,del(13) (q12q14) | HU | Rux | Y | 2/2/2010 | 66 | IV | MCL | R-hyper-CVAD/R-MTX/Ara-C | 67 mo |
| 8 | M | 11/20/2009 | No | JAK2 (87.1%) | 2463 | MF-3 | 46,XY,del(20) (q11.2q13.3) | HU | CYT387 | Y | 5/2/2017 | 77 | IV | MCL | R | 5.7 mo |
| 9 | M | 12/23/2010 | PV | lJAK2 (87.85%) | 1451 | Not done | Diploid | Phlebotomy | AZD1480 | Y | 8/10/2018 | 72 | II | DLBCL | R-CHOP | NR |
| Patient no. . | Sex . | MF Dx date . | Prior MPN . | Molecular (allele %) . | LDH at MF Dx . | Marrow fibrosis grade . | Cytogenetics at time of MF Dx . | Prior MPN therapies before JAK inhibitor . | JAK inhibitor received . | JAK inhibitor prior to lymphoma? . | Lymphoma Dx date . | Age at lymphoma Dx . | Lymphoma stage . | Lymphoma subtype . | Lymphoma treatment . | OS from lymphoma Dx . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 8/14/2000 | No | Not done | 569 | MF-2 | Diploid | HU | N/A | N | 3/22/2010 | 62 | I | Follicular lymphoma, grade 3A | Observation | 11 mo |
| 2 | M | 3/26/2012 | No | JAK2 (46.4%) | 1107 | MF-2 | Diploid | None | N/A | N | 4/12/2012 | 62 | IV | Enteropathy associated TCL | Observation | NR |
| 3 | F | 7/23/2013 | PV | JAK2 (42.1%) | 949 | MF-2 | 46,XX,t(9;15) (p24;q15) | HU+ phlebotomy | N/A | N | 9/3/2013 | 63 | IV | TCL, anaplastic, ALK− | CHOP | 1.6 mo |
| 4 | M | 3/9/2010 | PV | JAK2 (86%) | 916 | MF-2 | 46,XY,del(20) (q11.2q13.3) | None | Len + Rux | Y | 7/13/2015 | 54 | IV | DLBCL | R-EPOCH | Lost to follow-up |
| 5 | F | 11/30/2010 | No | Triple-negative MF | 763 | MF-2 | Diploid | None | Rux | Y | 1/15/2017 | 69 | Unknown | NHL (scalp) | Lost to follow-up | Lost to follow-up |
| 6 | M | 2/21/2006 | No | Not done | 1635 | MF-2 | Diploid | None | CEP-701 | Y | 8/7/2014 | 49 | IV | DLBCL | R-CHOP/HD MTX | 5.5 mo |
| 7 | M | 6/27/2008 | PV | JAK2 (82%) | 1134 | MF-3 | 46,XY,del(13) (q12q14) | HU | Rux | Y | 2/2/2010 | 66 | IV | MCL | R-hyper-CVAD/R-MTX/Ara-C | 67 mo |
| 8 | M | 11/20/2009 | No | JAK2 (87.1%) | 2463 | MF-3 | 46,XY,del(20) (q11.2q13.3) | HU | CYT387 | Y | 5/2/2017 | 77 | IV | MCL | R | 5.7 mo |
| 9 | M | 12/23/2010 | PV | lJAK2 (87.85%) | 1451 | Not done | Diploid | Phlebotomy | AZD1480 | Y | 8/10/2018 | 72 | II | DLBCL | R-CHOP | NR |
CHOP, cyclophosphamide, hydroxydaunorubicin (doxorubicin or adriamycin), oncovin (vincristine), prednisone; DLBCL, diffuse large B-cell lymphoma; Dx, diagnosis; F, female; HU, hydroxyurea; Len, lenalidomide; M, male; MCL, mantle cell lymphoma; MTX, methotrexate; NHL, non-Hodgkin lymphoma; NR, not reached; R-EPOCH, rituximab, etoposide phosphate, prednisone, vincristine sulfate (oncovin), cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin); R-hyper-CVAD, rituximab plus hyper-fractionated cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone; Rux, ruxolitinib; TCL, T-cell lymphoma.